Effect of 5-aminolevulinic acid photodynamic therapy on the expression of Toll-like receptor 4 and nuclear factor kappa B in condyloma acuminatum keratinocytes

Photodiagnosis Photodyn Ther. 2022 Mar:37:102614. doi: 10.1016/j.pdpdt.2021.102614. Epub 2021 Nov 3.

Abstract

Background: Condyloma acuminatum (CA) is a common sexually transmitted disease caused by human papillomaviruses. Five-aminolevulinic acid-photodynamic therapy (ALA-PDT) can promote the apoptosis of keratinocytes and inhibit proliferation; however, the effect of ALA-PDT on the immune mechanism of CA tissue is not well understood. In this study, we examined the changes in Toll-like receptor 4 (TRL4) and nuclear factor kappa B (NF-κB) expression in CA tissues before ALA-PDT treatment to determine its effects and possible immune mechanisms.

Methods: Immunohistochemistry (streptavidin-peroxidase) was used to detect the expression of TLR4 and NF-κB in the keratinocytes of the patients with CA before and after ALA-PDT treatment.

Results: Before treatment, the positive TLR4 and NF-κB expression rates in the keratinocytes of the patients with CA were 86.53% (45/52) and 94.23% (49/52), respectively, whereas after treatment, these rates were 44.23% (23/52) and 38.46% (20/52), respectively. Positive TLR4 and NF-κB expression in the keratinocytes of CA was mostly ++ to +++ in intensity before ALA-PDT and mostly ranged from - to + after treatment. The positive expression rate and intensity of TLR4 and NF-κB in the two groups before and after ALA-PDT were significantly different (P < 0.05). There was a positive correlation between the expression of TLR4 and NF-κB in the CA tissues after ALA-PDT (r = 0.486, P < 0.05).

Conclusions: ALA-PDT may relieve local immunosuppressive states by reducing TLR4 and NF-κB expression and jointly promoting CA regression, which is a potential molecular mechanism of ALA-PDT in CA treatment.

Keywords: 5-aminolevulinic acid photodynamic therapy; Condyloma acuminatum; Nuclear factor kappa B; Toll-like receptor 4.

MeSH terms

  • Aminolevulinic Acid* / metabolism
  • Aminolevulinic Acid* / pharmacology
  • Aminolevulinic Acid* / therapeutic use
  • Humans
  • Keratinocytes
  • NF-kappa B / metabolism
  • NF-kappa B / pharmacology
  • Photochemotherapy* / methods
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Toll-Like Receptor 4 / metabolism

Substances

  • NF-kappa B
  • Photosensitizing Agents
  • TLR4 protein, human
  • Toll-Like Receptor 4
  • Aminolevulinic Acid